Showing results (31-40 of 58) with videos related to
Sort By:
Pageof 6
Molecular Cancer Therapeutics|July 12, 2020
A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure LevelsRobyn M Barfield, Yun Cheol Kim, Stepan Chuprakov, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 5, 2005
Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxelAnne Gangloff, Wei-Ann Hsueh, Amanda L Kesner, et al.Oncotarget|December 2, 2016
Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancerMarzia A Locatelli, Philippe Aftimos, E Claire Dees, et al.Molecular Cancer Therapeutics|May 28, 2021
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric CancerMark D Pegram, Erika P Hamilton, Antoinette R Tan, et al.Cancer Medicine|March 9, 2019
Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patientsManjiri M Bakre, Charusheila Ramkumar, Arun Kumar Attuluri, et al.Biomaterials|September 22, 2025
Spontaneous upregulation of stemness and 3D spheroid formation of single cancer cells induced by scaffold-free polypeptide polyelectrolyte multilayer coatingJia-Yang Chen, Chia-Chun Liu, Lucas Wang, et al.Proceedings of the National Academy of Sciences of the United States of America|July 14, 2021
Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab toleranceRosalynd Upton, Allison Banuelos, Dongdong Feng, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2004
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patientsGottfried E Konecny, Y Gloria Meng, Michael Untch, et al.Carcinogenesis|June 25, 2011
Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancerTasha R Smith, Wen Liu-Mares, Beth O Van Emburgh, et al.Journal of the National Cancer Institute|May 20, 2004
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancerMark D Pegram, Tadeusz Pienkowski, Donald W Northfelt, et al.Pageof 6